Chaoxing He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chaoxing He has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Bai Xiang
Department of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China
2 shared publications Ge Chen
Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, PR China
1 shared publicationJia Wang
Department of Pharmaceutics, College of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, PR China
1 shared publication- Lei Wang
Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
1 shared publication Lirong Wang
Department of Pharmaceutics, College of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, PR China
1 shared publication- Lu Huang
Department of Pharmaceutics, School of Pharmaceutical Sciences, Hebei Medical University, Shijiazhuang 050017, China
1 shared publication
Latest Publications
- Open Access
- 19 February 2025
- Published by Elsevier in International Journal of Pharmaceutics: X
- Vol. 9, 100318
Neutrophils-mediated accelerated blood clearance phenomenon in beagles and rats based on the cross-injection of non-PEGylated and PEGylated nanoemulsions
- 19 February 2025
- Published by Elsevier in International Journal of Pharmaceutics: X
- Vol. 9, 100318
Open AccessNeutrophils-mediated accelerated blood clearance phenomenon in beagles and rats based on the cross-injection of non-PEGylated and PEGylated nanoemulsions
- Open Access
- 1 January 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (1) , 45
Innovative Lipid Nanoparticles Co-Delivering Hydroxychloroquine and siRNA for Enhanced Rheumatoid Arthritis Therapy
Background: Rheumatoid arthritis (RA) is a debilitating autoimmune disorder characterized by chronic inflammation and joint damage. Despite advancements in treatment, complete remission remains elusive. Methods: In this study, we introduce a novel lipid nanoparticle formulation co-delivering hydroxychloroquine (HCQ) and siRNA targeting TNF-α (siTNF-α) using microfluidic technology, marking the first use of such a combination for RA therapy. Results: In LPS-stimulated RAW 264.7 cells, the nanoparticles effectively reduced inflammatory markers. When administered via an intra-articular injection in a rat model, they significantly decreased joint inflammation and demonstrated good biological safety. Conclusions: This pioneering approach highlights the potential of lipid nanoparticles as a dual-delivery platform for enhanced RA treatment through targeted intra-articular administration.
- 1 January 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (1) , 45
Open AccessInnovative Lipid Nanoparticles Co-Delivering Hydroxychloroquine and siRNA for Enhanced Rheumatoid Arthritis Therapy
Background: Rheumatoid arthritis (RA) is a debilitating autoimmune disorder characterized by chronic inflammation and joint damage. Despite advancements in treatment, complete remission remains elusive. Methods: In this study, we introduce a novel lipid nanoparticle formulation co-delivering hydroxychloroquine (HCQ) and siRNA targeting TNF-α (siTNF-α) using microfluidic technology, marking the first use of such a combination for RA therapy. Results: In LPS-stimulated RAW 264.7 cells, the nanoparticles effectively reduced inflammatory markers. When administered via an intra-articular injection in a rat model, they significantly decreased joint inflammation and demonstrated good biological safety. Conclusions: This pioneering approach highlights the potential of lipid nanoparticles as a dual-delivery platform for enhanced RA treatment through targeted intra-articular administration.